SurModics (SRDX) Misses Q4 EPS by 10c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. USO
3. SPY
4. NVDA
5. OPCH
6. BBIO
7. GOOGL
8. AMD
9. CHRW
10. SKYD

Go back to SurModics (SRDX) Misses Q4 EPS by 10c, Revenues Beat

Surmodics Reports Fourth Quarter Fiscal 2020 Results

November 4, 2020 4:05 PM EST

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 fourth quarter ended September 30, 2020.

Summary of Fourth Quarter and Recent Highlights

Revenue of $22.5 million, a decrease of 27% year-over-year GAAP EPS of ($0.22), non-GAAP EPS of ($0.18) FDA clearance received for PounceTM Thrombus Retrieval System for non-surgical removal of clots from the peripheral arterial vasculature

I am proud of the meaningful progress our team... More